ABSTRACT
Only a few cases of pityriasis rosea (PR)/pityriasis rosea-like eruption (PRLE) after anti-SARS-CoV-2 vaccination have been reported. In the period May 2021- February 2022 we observed five cases of clinically typical PR that appeared 2 to 3 weeks after anti-SARS-CoV-2 vaccination with BNT162b2 (3 patients) or mRNA- 1273 (2 patients). In 4 patients PR appeared after the first vaccination; in one patient after the second one. In 3 patients a biopsy for histopathological examinations was carried out. Results were typical for PR. In all patients laboratory examinations were within normal ranges. All patients were treated with cetirizine. Complete remission was observed within 14-30 days. Four patients were subjected to the second vaccination, but no skin lesions appeared. All patients are currently in good general health. It is possible that a relationship between anti- Sars-CoV-2 vaccination and PR/PRLE exists; however, it is very rare, in consideration of millions of vaccinated subjects and the low number of reported cases of PR/PRLE. The pathogenesis of this relationship is unknown. However, some hypotheses may be advanced: PR/PRLE following anti-Sars-CoV-2 vaccination may be just a coincidence; anti-Sars-CoV-2 vaccines cause a reactivation of HHV-6 and/or HHV-7; vaccines can induce a delayed hypersensitivity response clinically similar to drug-induced PRLE.
Subject(s)
COVID-19 , Tinea , Humans , Pandemics , SARS-CoV-2 , Tinea/diagnosis , Tinea/epidemiologySubject(s)
COVID-19 , Sexually Transmitted Diseases/epidemiology , Chlamydia Infections/epidemiology , Condylomata Acuminata/epidemiology , Gonorrhea/epidemiology , HIV Infections/epidemiology , Herpes Genitalis/epidemiology , Humans , Italy/epidemiology , Mycoplasma Infections/epidemiology , Mycoplasma genitalium , SARS-CoV-2 , Syphilis/epidemiologySubject(s)
COVID-19 , Herpes Zoster , Herpes Zoster/complications , Herpesvirus 3, Human , Humans , SARS-CoV-2Subject(s)
COVID-19/diagnosis , Urticaria/virology , Acetaminophen/therapeutic use , Adult , Antiviral Agents/therapeutic use , Cetirizine/therapeutic use , Dermatologic Agents/therapeutic use , Drug Therapy, Combination , Female , Histamine H1 Antagonists, Non-Sedating/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , Male , Middle Aged , SARS-CoV-2 , Urticaria/drug therapy , COVID-19 Drug TreatmentSubject(s)
COVID-19/complications , Herpes Zoster/etiology , Adult , Aged , Female , Humans , Male , Middle AgedSubject(s)
COVID-19/complications , COVID-19/diagnosis , Pityriasis Rosea/virology , Adult , Humans , Male , SARS-CoV-2 , Young AdultSubject(s)
COVID-19/prevention & control , Dermatitis, Seborrheic/etiology , Masks/adverse effects , Adult , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, overall similarities in the clinical presentation of these dermatological manifestations have not yet been summarized. OBJECTIVE: This review aims to provide an overview of various cutaneous manifestations in patients with COVID-19 through three case reports and a literature review. METHODS: A literature search was conducted using PubMed, OVID, and Google search engines for original and review articles. Studies written in the English language that mentioned cutaneous symptoms and COVID-19 were included. RESULTS: Eighteen articles and three additional cases reported in this paper were included in this review. Of these studies, 6 are case series and 12 are case report studies. The most common cutaneous manifestation of COVID-19 was found to be maculopapular exanthem (morbilliform), presenting in 36.1% (26/72) patients. The other cutaneous manifestations included: a papulovesicular rash (34.7%, 25/72), urticaria (9.7%, 7/72), painful acral red purple papules (15.3%, 11/72) of patients, livedo reticularis lesions (2.8%, 2/72) and petechiae (1.4%, 1/72). Majority of lesions were localized on the trunk (66.7%, 50/72), however, 19.4% (14/72) of patients experienced cutaneous manifestations in the hands and feet. Skin lesion development occurred before the onset of respiratory symptoms or COVID-19 diagnosis in 12.5% (9/72) of the patients, and lesions spontaneously healed in all patients within 10 days. Majority of the studies reported no correlation between COVID-19 severity and skin lesions. CONCLUSION: Infection with COVID-19 may result in dermatological manifestations with various clinical presentations, which may aid in the timely diagnosis of this infection.